Changes in Gastrointestinal Hormones and Leptin after Roux-en-Y Gastric Bypass Procedure: A Review

Journal of the American Dietetic Association

Volumn 110, Issue 4, 2010, Pages 571-584

  Beckman, Lauren M ^a   Beckman, Tiffany R ^a   Earthman, Carrie P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; PEPTIDE YY;

ARTICLE; BLOOD; FOLLOW UP; FOOD INTAKE; HUMAN; MORBID OBESITY; PHYSIOLOGY; STOMACH BYPASS; TREATMENT OUTCOME; WEIGHT REDUCTION;

APPETITE REGULATION; FOLLOW-UP STUDIES; GASTRIC BYPASS; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LEPTIN; OBESITY, MORBID; PEPTIDE YY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 77949554717     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jada.2009.12.023     Document Type: Article

References (85)

1. Obesity and overweight. World Health Organization Web site. http://www.who.int/mediacentre/factsheets/fs311/en/index.html Accessed November 25, 2008
2. Smith B.R., Schauer P., and Nguyen N.T. Surgical approaches to the treatment of obesity: Bariatric surgery. Endocrinol Metab Clin North Am. 37 (2008) 943-964
3. Elder K.A., and Wolfe B.M. Bariatric surgery: A review of procedures and outcomes. Gastroenterology 132 (2007) 2253-2271
4. Buchwald H., and Consensus Conference Panel. Consensus conference statement bariatric surgery for morbid obesity: Health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis. 1 (2005) 371-381
5. Drucker D.J. The role of gut hormones in glucose homeostasis. J Clin Invest. 117 (2007) 24-32
6. Borg C.M., le Roux C.W., Ghatei M.A., Bloom S.R., Patel A.G., and Aylwin S.J. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 93 (2006) 210-215
7. Holdstock C., Zethelius B., Sundbom M., Karlsson F.A., and Eden Engstrom B. Postprandial changes in gut regulatory peptides in gastric bypass patients. Int J Obes (Lond) 32 (2008) 1640-1646
8. Murphy K.G., and Bloom S.R. Gut hormones and the regulation of energy homeostasis. Nature 444 (2006) 854-859
9. Wren A.M., and Bloom S.R. Gut hormones and appetite control. Gastroenterology 132 (2007) 2116-2130
10. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
11. Cummings D.E., and Overduin J. Gastrointestinal regulation of food intake. J Clin Invest. 117 (2007) 13-23
12. Frezza E.E., Wachtel M.S., and Chiriva-Internati M. The multiple faces of glucagon-like peptide-1-Obesity, appetite, and stress: What is next?. A review. Dig Dis Sci. 52 (2007) 643-649
13. Dhillo W.S. Appetite regulation: An overview. Thyroid 17 (2007) 433-445
14. Vincent R.P., Ashrafian H., and le Roux C.W. Mechanisms of disease: The role of gastrointestinal hormones in appetite and obesity. Nat Clin Pract Gastroenterol Hepatol. 5 (2008) 268-277
15. Vincent R.P., and le Roux C.W. The satiety hormone peptide YY as a regulator of appetite. J Clin Pathol. 61 (2008) 548-552
16. Vincent R.P., and le Roux C.W. Changes in gut hormones after bariatric surgery. Clin Endocrinol (Oxf) 69 (2008) 173-179
17. Jayasena C.N., and Bloom S.R. Role of gut hormones in obesity. Endocrinol Metab Clin North Am. 37 (2008) 769-787 xi
18. Meier J.J., and Nauck M.A. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev. 21 (2005) 91-117
19. Ma X., Bruning J., and Ashcroft F.M. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci. 27 (2007) 7125-7129
20. Pannacciulli N., Le D.S., Salbe A.D., Chen K., Reiman E.M., Tataranni P.A., and Krakoff J. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage 35 (2007) 511-517
21. Van Citters G.W., and Lin H.C. The ileal brake: A 15-year progress report. Curr Gastroenterol Rep. 1 (1999) 404-409
22. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., Winterhalder R., Conen D., and Beglinger C. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 44 (1999) 81-86
23. Naslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., Rossner S., and Hellstrom P.M. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 23 (1999) 304-311
24. Verdich C., Toubro S., Buemann B., Lysgard Madsen J., Juul Holst J., and Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-Effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 25 (2001) 1206-1214
25. Feinle C., Chapman I.M., Wishart J., and Horowitz M. Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23 (2002) 1491-1495
26. le Roux C.W., and Bloom S.R. Peptide YY, appetite and food intake. Proc Nutr Soc. 64 (2005) 213-216
27. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., Wren A.M., Brynes A.E., Low M.J., Ghatei M.A., Cone R.D., and Bloom S.R. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
28. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., Ghatei M.A., and Bloom S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 349 (2003) 941-948
29. le Roux C.W., Batterham R.L., Aylwin S.J., Patterson M., Borg C.M., Wynne K.J., Kent A., Vincent R.P., Gardiner J., Ghatei M.A., and Bloom S.R. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147 (2006) 3-8
30. Kim B.J., Carlson O.D., Jang H.J., Elahi D., Berry C., and Egan J.M. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab. 90 (2005) 6665-6671
31. Stock S., Leichner P., Wong A.C., Ghatei M.A., Kieffer T.J., Bloom S.R., and Chanoine J.P. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab. 90 (2005) 2161-2168
32. Friedman J.M. Obesity in the new millennium. Nature 404 (2000) 632-634
33. Bloomgarden Z.T. Gut and adipocyte peptides. Diabetes Care 29 (2006) 450-456
34. Akamizu T., Shinomiya T., Irako T., Fukunaga M., Nakai Y., Nakai Y., and Kangawa K. Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab. 90 (2005) 6-9
35. Zwirska-Korczala K., Konturek S.J., Sodowski M., Wylezol M., Kuka D., Sowa P., Adamczyk-Sowa M., Kukla M., Berdowska A., Rehfeld J.F., Bielanski W., and Brzozowski T. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol. 58 suppl 1 (2007) 13-35
36. Hansen T.K., Dall R., Hosoda H., Kojima M., Kangawa K., Christiansen J.S., and Jorgensen J.O. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 56 (2002) 203-206
37. Cummings D.E., Weigle D.S., Frayo R.S., Breen P.A., Ma M.K., Dellinger E.P., and Purnell J.Q. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 346 (2002) 1623-1630
38. Cummings D.E., Foster-Schubert K.E., and Overduin J. Ghrelin and energy balance: Focus on current controversies. Curr Drug Targets 6 (2005) 153-169
39. English P.J., Ghatei M.A., Malik I.A., Bloom S.R., and Wilding J.P. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 87 (2002) 2984
40. Weigle D.S., Duell P.B., Connor W.E., Steiner R.A., Soules M.R., and Kuijper J.L. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J Clin Endocrinol Metab. 82 (1997) 561-565
41. Goldfine A.B., Mun E.C., Devine E., Bernier R., Baz-Hecht M., Jones D.B., Schneider B.E., Holst J.J., and Patti M.E. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab. 92 (2007) 4678-4685
42. Korner J., Bessler M., Inabnet W., Taveras C., and Holst J.J. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg.Obes. Relat.Dis. 3 (2007) 597-601
43. Laferrere B., Heshka S., Wang K., Khan Y., McGinty J., Teixeira J., Hart A.B., and Olivan B. Incretin levels and effect are markedly enhanced 1 month after roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30 (2007) 1709-1716
44. Laferrere B., Teixeira J., McGinty J., Tran H., Egger J.R., Colarusso A., Kovack B., Bawa B., Koshy N., Lee H., Yapp K., and Olivan B. Effect of weight loss by gastric bypass surgery vs hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 93 (2008) 2479-2485
45. le Roux C.W., Aylwin S.J., Batterham R.L., Borg C.M., Coyle F., Prasad V., Shurey S., Ghatei M.A., Patel A.G., and Bloom S.R. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 243 (2006) 108-114
46. le Roux C.W., Welbourn R., Werling M., Osborne A., Kokkinos A., Laurenius A., Lonroth H., Fandriks L., Ghatei M.A., Bloom S.R., and Olbers T. Gut hormones as mediators of appetite and weight loss after roux-en-Y gastric bypass. Ann Surg. 246 (2007) 780-785
47. Morinigo R., Moize V., Musri M., Lacy A.M., Navarro S., Marin J.L., Delgado S., Casamitjana R., and Vidal J. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 91 (2006) 1735-1740
48. Reinehr T., Roth C.L., Schernthaner G.H., Kopp H.P., Kriwanek S., and Schernthaner G. Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically induced weight loss. Obes Surg. 17 (2007) 1571-1577
49. Rodieux F., Giusti V., D'Alessio D.A., Suter M., and Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 16 (2008) 298-305
50. Morinigo R., Lacy A.M., Casamitjana R., Delgado S., Gomis R., and Vidal J. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg. 16 (2006) 1594-1601
51. Naslund E., and Kral J. Impact of gastric bypass surgery on gut hormones and glucose homeostasis in type 2 diabetes. Diabetes 55 suppl (2006) S92-S97
52. Cummings D.E., Overduin J., and Foster-Schubert K.E. Gastric bypass for obesity: Mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 89 (2004) 2608-2615
53. Clements R.H., Gonzalez Q.H., Long C.I., Wittert G., and Laws H.L. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg. 70 (2004) 1-4
54. Rubino F., Gagner M., Gentileschi P., Kini S., Fukuyama S., Feng J., and Diamond E. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 240 (2004) 236-242
55. Whitson B.A., Leslie D.B., Kellogg T.A., Maddaus M.A., Buchwald H., Billington C.J., and Ikramuddin S. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: A preliminary study. J Surg Res. 141 (2007) 31-39
56. Chan J.L., Mun E.C., Stoyneva V., Mantzoros C.S., and Goldfine A.B. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 14 (2006) 194-198
57. Korner J., Bessler M., Cirilo L.J., Conwell I.M., Daud A., Restuccia N.L., and Wardlaw S.L. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab. 90 (2005) 359-365
58. Korner J., Inabnet W., Conwell I.M., Taveras C., Daud A., Olivero-Rivera L., Restuccia N.L., and Bessler M. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 14 (2006) 1553-1561
59. Morinigo R., Vidal J., Lacy A.M., Delgado S., Casamitjana R., and Gomis R. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg. 247 (2008) 270-275
60. Karamanakos S.N., Vagenas K., Kalfarentzos F., and Alexandrides T.K. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: A prospective, double blind study. Ann Surg. 247 (2008) 401-407
61. Fruhbeck G., Diez-Caballero A., Gil M.J., Montero I., Gomez-Ambrosi J., Salvador J., and Cienfuegos J.A. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg. 14 (2004) 606-612
62. Fruhbeck G., Rotellar F., Hernandez-Lizoain J.L., Gil M.J., Gomez-Ambrosi J., Salvador J., and Cienfuegos J.A. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 14 (2004) 1208-1215
63. Molina A., Vendrell J., Gutierrez C., Simon I., Masdevall C., Soler J., and Gomez J.M. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg. 13 (2003) 615-621
64. Morinigo R., Casamitjana R., Moize V., Lacy A.M., Delgado S., Gomis R., and Vidal J. Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res. 12 (2004) 1108-1116
65. Stoeckli R., Chanda R., Langer I., and Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res. 12 (2004) 346-350
66. Vendrell J., Broch M., Vilarrasa N., Molina A., Gomez J.M., Gutierrez C., Simon I., Soler J., and Richart C. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes Res. 12 (2004) 962-971
67. Riedl M., Vila G., Maier C., Handisurya A., Shakeri-Manesch S., Prager G., Wagner O., Kautzky-Willer A., Ludvik B., Clodi M., and Luger A. Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab. 93 (2008) 2307-2312
68. Meier C.A., Bobbioni E., Gabay C., Assimacopoulos-Jeannet F., Golay A., and Dayer J.M. IL-1 receptor antagonist serum levels are increased in human obesity: A possible link to the resistance to leptin?. J Clin Endocrinol Metab. 87 (2002) 1184-1188
69. Hickey M.S., Pories W.J., MacDonald Jr. K.G., Cory K.A., Dohm G.L., Swanson M.S., Israel R.G., Barakat H.A., Considine R.V., Caro J.F., and Houmard J.A. A new paradigm for type 2 diabetes mellitus: Could it be a disease of the foregut?. Ann Surg. 227 (1998) 637-643
70. Faraj M., Jones P., Sniderman A.D., and Cianflone K. Enhanced dietary fat clearance in postobese women. J Lipid Res. 42 (2001) 571-580
71. Czupryniak L., Pawlowski M., Kumor A., Szymanski D., Loba J., and Strzelczyk J. Predicting maximum roux-en-Y gastric bypass-induced weight reduction-Preoperative plasma leptin or body weight?. Obes Surg. 17 (2007) 162-167
72. Ramos A.P., de Abreu M.R., Vendramini R.C., Brunetti I.L., and Pepato M.T. Decrease in circulating glucose, insulin and leptin levels and improvement in insulin resistance at 1 and 3 months after gastric bypass. Obes Surg. 16 (2006) 1359-1364
73. Swarbrick M.M., Stanhope K.L., Austrheim-Smith I.T., Van Loan M.D., Ali M.R., Wolfe B.M., and Havel P.J. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 51 (2008) 1901-1911
74. Das S.K., Roberts S.B., McCrory M.A., Hsu L.K., Shikora S.A., Kehayias J.J., Dallal G.E., and Saltzman E. Long-term changes in energy expenditure and body composition after massive weight loss induced by gastric bypass surgery. Am J Clin Nutr. 78 (2003) 22-30
75. Whitson B.A., Leslie D.B., Kellogg T.A., Maddaus M.A., Buchwald H., Billington C.J., and Ikramuddin S. Adipokine response in diabetics and nondiabetics following the roux-en-Y gastric bypass: A preliminary study. J Surg Res. 142 (2007) 295-300
76. Bobbioni-Harsch E., Morel P., Huber O., Assimacopoulos-Jeannet F., Chassot G., Lehmann T., Volery M., and Golay A. Energy economy hampers body weight loss after gastric bypass. J Clin Endocrinol Metab. 85 (2000) 4695-4700
77. Christou N.V., Look D., and McLean A.P. Pre- and post-prandial plasma ghrelin levels do not correlate with satiety or failure to achieve a successful outcome after Roux-en-Y gastric bypass. Obes Surg. 15 (2005) 1017-1023
78. Couce M.E., Cottam D., Esplen J., Schauer P., and Burguera B. Is ghrelin the culprit for weight loss after gastric bypass surgery?. A negative answer. Obes Surg. 16 (2006) 870-878
79. Engstrom B.E., Ohrvall M., Sundbom M., Lind L., and Karlsson F.A. Meal suppression of circulating ghrelin is normalized in obese individuals following gastric bypass surgery. Int. J. Obes. (Lond) 31 (2007) 476-480
80. Foschi D., Corsi F., Colombo F., Vago T., Bevilaqua M., Rizzi A., and Trabucchi E. Different effects of vertical banded gastroplasty and roux-en-Y gastric bypass on meal inhibition of ghrelin secretion in morbidly obese patients. J Invest Surg. 21 (2008) 77-81
81. Leonetti F., Silecchia G., Iacobellis G., Ribaudo M.C., Zappaterreno A., Tiberti C., Iannucci C.V., Perrotta N., Bacci V., Basso M.S., Basso N., and Di Mario U. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab. 88 (2003) 4227-4231
82. Lin E., Gletsu N., Fugate K., McClusky D., Gu L.H., Zhu J.L., Ramshaw B.J., Papanicolaou D.A., Ziegler T.R., and Smith C.D. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg. 139 (2004) 780-784
83. Mancini M.C., Costa A.P., de Melo M.E., Cercato C., Giannella-Neto D., Garrido Jr. A.B., Rosberg S., Albertsson-Wikland K., Villares S.M., and Halpern A. Effect of gastric bypass on spontaneous growth hormone and ghrelin release profiles. Obesity (Silver Spring) 14 (2006) 383-387
84. Sundbom M., Holdstock C., Engstrom B.E., and Karlsson F.A. Early changes in ghrelin following Roux-en-Y gastric bypass: Influence of vagal nerve functionality?. Obes Surg. 17 (2007) 304-310
85. Tritos N.A., Mun E., Bertkau A., Grayson R., Maratos-Flier E., and Goldfine A. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res. 11 (2003) 919-924